Berberine in traditional Chinese medicine: Modulating gut microbiota for gout management - mechanisms and clinical perspectives

Gout, a metabolic inflammatory arthritis driven by hyperuricemia, has rising global prevalence linked to high-purine and high-fructose diets. Gut dysbiosis, characterized by depleted beneficial microbes and overgrown pathogenic strains, disrupts uric acid (UA) excretion and exacerbates systemic inflammation, serving as a core pathological driver of gout. Conventional Western anti-gout drugs only relieve transient symptoms and carry severe side effects, whereas berberine (BBR), a bioactive alkaloid from traditional Chinese medicine (TCM), exerts multi-target anti-gout activity via gut microbiota regulation; however, its integrated intestinal mechanisms remain unsystematically summarized. This review elucidates the multi-pathway mechanisms through which BBR ameliorates gout by remodeling gut microbiota homeostasis and discusses its clinical translational prospects for gout management. This review retrieved English (PubMed, Web of Science, Scopus, EMBASE) and Chinese (CNKI, Wanfang) databases for peer-reviewed in vitro, animal and clinical studies published up to December 2024, combining gut microbiota, UA metabolism and berberine-related keywords; case reports, abstracts and duplicate papers were excluded. BBR restores intestinal microecology by elevating beneficial bacteria (Lactobacillus, Akkermansia, Bifidobacterium) and suppressing pro-inflammatory pathogens. It boosts butyrate production, upregulates intestinal ABCG2 to accelerate UA fecal excretion, and directly inhibits xanthine oxidase to reduce UA synthesis. Gut microbiota biotransforms BBR into DHB, OBR and other derivatives with higher bioavailability; these metabolites further inhibit renal UA reabsorption and block NLRP3 inflammasome activation to lower IL-1β/IL-18. The bidirectional BBR-microbiota interaction creates a positive feedback loop that amplifies hypouricemic and anti-inflammatory effects. BBR achieves comprehensive gout intervention via gut microbiota-centered multi-target regulation, representing a promising TCM-derived therapeutic strategy. Restricted oral bioavailability and insufficient large-scale human clinical data currently limit its clinical application; novel delivery systems, probiotic combination therapy and long-term clinical trials are required to advance its translational use in gout treatment.

Authors

Publication Details

Journal
Pakistan Journal of Pharmaceutical Sciences
Published
2026-11-21
DOI
https://doi.org/10.36721/pjps/2026.40.15219.1
Primary Topic
Gout, Hyperuricemia, Uric Acid
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Berberine in traditional Chinese medicine: Modulating gut microbiota for gout management - mechanisms and clinical perspectives

Guoming Wang
Pakistan Journal of Pharmaceutical Sciences
Gout, Hyperuricemia, Uric Acid
article

Berberine in traditional Chinese medicine: Modulating gut microbiota for gout management - mechanisms and clinical perspectives

Guoming Wang
article en

Abstract

Gout, a metabolic inflammatory arthritis driven by hyperuricemia, has rising global prevalence linked to high-purine and high-fructose diets. Gut dysbiosis, characterized by depleted beneficial microbes and overgrown pathogenic strains, disrupts uric acid (UA) excretion and exacerbates systemic inflammation, serving as a core pathological driver of gout. Conventional Western anti-gout drugs only relieve transient symptoms and carry severe side effects, whereas berberine (BBR), a bioactive alkaloid from traditional Chinese medicine (TCM), exerts multi-target anti-gout activity via gut microbiota regulation; however, its integrated intestinal mechanisms remain unsystematically summarized. This review elucidates the multi-pathway mechanisms through which BBR ameliorates gout by remodeling gut microbiota homeostasis and discusses its clinical translational prospects for gout management. This review retrieved English (PubMed, Web of Science, Scopus, EMBASE) and Chinese (CNKI, Wanfang) databases for peer-reviewed in vitro, animal and clinical studies published up to December 2024, combining gut microbiota, UA metabolism and berberine-related keywords; case reports, abstracts and duplicate papers were excluded. BBR restores intestinal microecology by elevating beneficial bacteria (Lactobacillus, Akkermansia, Bifidobacterium) and suppressing pro-inflammatory pathogens. It boosts butyrate production, upregulates intestinal ABCG2 to accelerate UA fecal excretion, and directly inhibits xanthine oxidase to reduce UA synthesis. Gut microbiota biotransforms BBR into DHB, OBR and other derivatives with higher bioavailability; these metabolites further inhibit renal UA reabsorption and block NLRP3 inflammasome activation to lower IL-1β/IL-18. The bidirectional BBR-microbiota interaction creates a positive feedback loop that amplifies hypouricemic and anti-inflammatory effects. BBR achieves comprehensive gout intervention via gut microbiota-centered multi-target regulation, representing a promising TCM-derived therapeutic strategy. Restricted oral bioavailability and insufficient large-scale human clinical data currently limit its clinical application; novel delivery systems, probiotic combination therapy and long-term clinical trials are required to advance its translational use in gout treatment.

Pakistan Journal of Pharmaceutical Sciences
Gout, Hyperuricemia, Uric Acid
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Berberine in traditional Chinese medicine: Modulating gut microbiota for gout management - mechanisms and clinical perspectives — Guoming Wang · Pakistan Journal of Pharmaceutical Sciences (2026) | TGRS Research Map | TGRS